Regulatory T cells

Hideya Onishi, Takashi Morisaki, Mitsuo Katano

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Regulatory T cells (Tregs) are CD4+ T cells that inhibit autoreactive effector T cells to suppress antitumor immunity. Many anticancer therapeutics have limited efficacy, and it is thought that Tregs may, in part, be one of the reasons. From this viewpoint, Tregs may be a therapeutic target for cancer immunotherapy. Tregs also play a pivotal role in the induction of self-tolerance, and their dysfunction may lead to autoimmune disease. Promising results have recently been reported on the molecular targeting of drugs to Tregs. In the near future, the regulation of Tregs may be a central point for cancer immunotherapy. In this chapter, we focus on the immune-suppressing mechanism of Tregs and the development of strategies to modulate Tregs.

Original languageEnglish
Title of host publicationImmunotherapy of Cancer
Subtitle of host publicationAn Innovative Treatment Comes of Age
PublisherSpringer Japan
Pages309-322
Number of pages14
ISBN (Electronic)9784431550310
ISBN (Print)9784431550303
DOIs
Publication statusPublished - Feb 22 2016

Fingerprint

Regulatory T-Lymphocytes
Immunotherapy
T-Lymphocytes
Self Tolerance
Drug Delivery Systems
Autoimmune Diseases
Immunity
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Onishi, H., Morisaki, T., & Katano, M. (2016). Regulatory T cells. In Immunotherapy of Cancer: An Innovative Treatment Comes of Age (pp. 309-322). Springer Japan. https://doi.org/10.1007/978-4-431-55031-0_21

Regulatory T cells. / Onishi, Hideya; Morisaki, Takashi; Katano, Mitsuo.

Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, 2016. p. 309-322.

Research output: Chapter in Book/Report/Conference proceedingChapter

Onishi, H, Morisaki, T & Katano, M 2016, Regulatory T cells. in Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, pp. 309-322. https://doi.org/10.1007/978-4-431-55031-0_21
Onishi H, Morisaki T, Katano M. Regulatory T cells. In Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan. 2016. p. 309-322 https://doi.org/10.1007/978-4-431-55031-0_21
Onishi, Hideya ; Morisaki, Takashi ; Katano, Mitsuo. / Regulatory T cells. Immunotherapy of Cancer: An Innovative Treatment Comes of Age. Springer Japan, 2016. pp. 309-322
@inbook{ea1139e352ef4696bf4a9dee77b65581,
title = "Regulatory T cells",
abstract = "Regulatory T cells (Tregs) are CD4+ T cells that inhibit autoreactive effector T cells to suppress antitumor immunity. Many anticancer therapeutics have limited efficacy, and it is thought that Tregs may, in part, be one of the reasons. From this viewpoint, Tregs may be a therapeutic target for cancer immunotherapy. Tregs also play a pivotal role in the induction of self-tolerance, and their dysfunction may lead to autoimmune disease. Promising results have recently been reported on the molecular targeting of drugs to Tregs. In the near future, the regulation of Tregs may be a central point for cancer immunotherapy. In this chapter, we focus on the immune-suppressing mechanism of Tregs and the development of strategies to modulate Tregs.",
author = "Hideya Onishi and Takashi Morisaki and Mitsuo Katano",
year = "2016",
month = "2",
day = "22",
doi = "10.1007/978-4-431-55031-0_21",
language = "English",
isbn = "9784431550303",
pages = "309--322",
booktitle = "Immunotherapy of Cancer",
publisher = "Springer Japan",
address = "Japan",

}

TY - CHAP

T1 - Regulatory T cells

AU - Onishi, Hideya

AU - Morisaki, Takashi

AU - Katano, Mitsuo

PY - 2016/2/22

Y1 - 2016/2/22

N2 - Regulatory T cells (Tregs) are CD4+ T cells that inhibit autoreactive effector T cells to suppress antitumor immunity. Many anticancer therapeutics have limited efficacy, and it is thought that Tregs may, in part, be one of the reasons. From this viewpoint, Tregs may be a therapeutic target for cancer immunotherapy. Tregs also play a pivotal role in the induction of self-tolerance, and their dysfunction may lead to autoimmune disease. Promising results have recently been reported on the molecular targeting of drugs to Tregs. In the near future, the regulation of Tregs may be a central point for cancer immunotherapy. In this chapter, we focus on the immune-suppressing mechanism of Tregs and the development of strategies to modulate Tregs.

AB - Regulatory T cells (Tregs) are CD4+ T cells that inhibit autoreactive effector T cells to suppress antitumor immunity. Many anticancer therapeutics have limited efficacy, and it is thought that Tregs may, in part, be one of the reasons. From this viewpoint, Tregs may be a therapeutic target for cancer immunotherapy. Tregs also play a pivotal role in the induction of self-tolerance, and their dysfunction may lead to autoimmune disease. Promising results have recently been reported on the molecular targeting of drugs to Tregs. In the near future, the regulation of Tregs may be a central point for cancer immunotherapy. In this chapter, we focus on the immune-suppressing mechanism of Tregs and the development of strategies to modulate Tregs.

UR - http://www.scopus.com/inward/record.url?scp=85030155347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030155347&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55031-0_21

DO - 10.1007/978-4-431-55031-0_21

M3 - Chapter

AN - SCOPUS:85030155347

SN - 9784431550303

SP - 309

EP - 322

BT - Immunotherapy of Cancer

PB - Springer Japan

ER -